PAXG shows superior efficacy over mFOLFIRINOX for patients with resectable pancreatic ductal adenocarcinoma.

• Median event-free survival (EFS) for PAXG is 16.0 months compared to 10.2 months for mFOLFIRINOX.
• EFS hazard ratio is 0.63, indicating a significant benefit for PAXG (p=0.0018).

Surgeons should consider PAXG as the preferred preoperative chemotherapy regimen for this patient population.

• Adverse events were similar between both groups, suggesting PAXG’s safety profile remains acceptable.